دورية أكاديمية
أعرض في EDS

Updated recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer.

التفاصيل البيبلوغرافية
العنوان: Updated recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer.
المؤلفون: Climent MÁ; Instituto Valenciano de Oncología (IVO), Valencia, Spain. Electronic address: macliment@fivo.org., León-Mateos L; Complexo Hospitalario Universitario de Pontevedra, Pontevedra, Spain., González Del Alba A; Hospital Universitario Son Espases, Palma de Mallorca, Spain., Pérez-Valderrama B; Hospital Universitario Virgen del Rocío, Sevilla, Spain., Méndez-Vidal MJ; Hospital Universitario Reina Sofía, Córdoba, Spain., Mellado B; Hospital Clínic, IDIBAPS, Barcelona, Spain., Arranz JÁ; Hospital General Universitario Gregorio Marañón, Madrid, Spain., Sánchez-Hernández A; Consorcio Hospitalario Provincial de Castellón, Castellón, Spain., Cassinello J; Hospital Universitario de Guadalajara, Guadalajara, Spain., Olmos D; Spanish National Cancer Research Centre (CNIO), Madrid, Spain., Carles J; Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain.
المصدر: Critical reviews in oncology/hematology [Crit Rev Oncol Hematol] 2015 Nov; Vol. 96 (2), pp. 308-18. Date of Electronic Publication: 2015 Jun 08.
نوع المنشور: Journal Article; Practice Guideline; Research Support, Non-U.S. Gov't; Review
اللغة: English
بيانات الدورية: Publisher: Elsevier Scientific Publishers Country of Publication: Netherlands NLM ID: 8916049 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0461 (Electronic) Linking ISSN: 10408428 NLM ISO Abbreviation: Crit Rev Oncol Hematol Subsets: MEDLINE
أسماء مطبوعة: Publication: <2005->: Amsterdam : Elsevier Scientific Publishers
Original Publication: Boca Raton, Fla. : CRC Press, 1983-
مواضيع طبية MeSH: Prostatic Neoplasms, Castration-Resistant/*therapy, Antineoplastic Agents/therapeutic use ; Humans ; Male
مستخلص: Prostate cancer is the most prevalent male urogenital malignancy. Approximately 30% of patients with prostate cancer will develop advanced disease. Androgen deprivation therapy achieves disease control in about 90% of these patients, but the majority of them will eventually develop progressive disease, a status called castration-resistant prostate carcinoma (CRPC). However, in recent years, several new therapy strategies, such as immunotherapy, hormonal manipulations, chemotherapy agents and some bone-targeted therapies, have demonstrated an improvement in terms of overall survival in controlled trials. In 2012, the Spanish Oncology Genitourinary Group (SOGUG) published its recommendations for the treatment of patients with CRPC. Due to the recent appearance of important new data and the complexity of decision-making in this field, SOGUG herein provides updated recommendations for the treatment of patients with metastatic prostate cancer.
(Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.)
فهرسة مساهمة: Keywords: Asymptomatic; Castration-resistant prostate carcinoma; Chemotherapy; Hormonal therapies; Recommendations; Symptomatic
المشرفين على المادة: 0 (Antineoplastic Agents)
تواريخ الأحداث: Date Created: 20150624 Date Completed: 20161213 Latest Revision: 20161230
رمز التحديث: 20240628
DOI: 10.1016/j.critrevonc.2015.05.019
PMID: 26100652
قاعدة البيانات: MEDLINE
كن أول من يترك تعليقا!
يجب تسجيل دخولك أولا